Loading clinical trials...

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00090090•Spectrum Pharmaceuticals, Inc

View on ClinicalTrials.gov

Summary

To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma
•at least one prior cytotoxic chemotherapy regimens
•measurable disease
•adequate bone marrow, liver and kidney function
•ECOG PS 0-2

Exclusion Criteria

•prior treatment with elsamitrucin
•prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment
•HIV positive or known AIDS syndrome
•uncontrolled medical disease or psychiatric condition/s

Locations (7)

Alta Bates Cancer Center

Berkeley, California, United States

Providence Saint Joseph Medical Center

Burbank, California, United States

USC Norris Cancer Center

Los Angeles, California, United States

Tower Hematology Oncology Medical Group

Los Angeles, California, United States

North Valley Hematology Oncology Medical Group

Mission Hills, California, United States

Cancer and Blood Institute Medical Group

Rancho Mirage, California, United States

North Shores University Hospital

Manhasset, New York, United States

Key Dates

Start Date

April 1, 2004

Completion Date

October 1, 2006

Last Updated

January 15, 2008

Enrollment

114

Estimated participants

Conditions

Mantle Cell LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

Elsamitrucin

DRUG

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Mantle Cell LymphomaNon Hodgkin Lymphoma+1 more

View study

RECRUITINGPHASE2

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

NCT06263491

Mantle Cell Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

A Long-term Extension Study of PCI-32765 (Ibrutinib)